Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Seizure drug may shield the brain after cardiac arrest — a trial puts it to the test

NCT ID NCT06401707

Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

After a cardiac arrest, many survivors develop seizures that can worsen brain injury. This trial tests whether giving the drug perampanel soon after resuscitation can prevent those seizures. About 52 adults who are comatose after a cardiac arrest will receive either perampanel or a placebo for five days. The study will check if the drug is safe and feasible to use in this setting, and whether it reduces the number of seizures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
perampanel (also known as Fycompa), a drug that blocks AMPA glutamate receptors in the brain
What this could lead to
If it works, this could point toward a way to prevent brain-damaging seizures after cardiac arrest, potentially improving survival and recovery.
What could go wrong
This is a small early-stage trial focused on safety and feasibility, so it is too soon to know if perampanel truly prevents seizures or improves outcomes. The drug may also cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years old * Non-traumatic, out-of-hospital cardiac arrest * Comatose on admission - defined as not following commands * Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest) * Admission to the intensive care unit at Zuckerberg San Francisco General Hospital Exclusion Criteria: * Acute cerebral hemorrhage or infarction * Pregnancy * Prisoner * Severe kidney function impairment with creatinine clearance inferior to 30 ml/min * Severe liver impairment with liver function tests five times above the upper limit of normal * Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart arrest are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiac arrest epilepsy Status Epilepticus visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart arrest Seizures Status epilepticus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Zuckerberg San Francisco General Hospital

    RECRUITING

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.